68

Cabio Biotech Wuhan Co LtdSHG 688089 Stock Report

Last reporting period 30 Sep, 2023

Updated 22 Oct, 2024

Last price

Market cap $B

0.748

Micro

Exchange

XSHG - Shanghai Stock Exchange

688089.SS Stock Analysis

68

Uncovered

Cabio Biotech Wuhan Co Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

70/100

Moderate score

Market cap $B

0.748

Dividend yield

3.12 %

Shares outstanding

120 B

Cabio Biotech Wuhan Co Ltd is a China-based company principally engaged in biotechnology business. The Company is mainly engaged in the research and development, production and sales of polyunsaturated fatty acids arachidonic acid (ARA), algal oil docosahexaenoic acid (DHA) and sialic acid (SA), and natural beta-carotene products. Its products are mainly used in infant formula food, dietary supplements, nutritional health food and formula food for special medical purposes. The Company integrates industrial strain-oriented optimization technology, fermentation fine control technology, and efficient separation, purification and preparation technology, and provides nutrient products and innovative solutions for customers in the global nutrition and health field through sustainable microbial synthesis and manufacturing methods. The Company mainly conducts its business in domestic and overseas markets.

View Section: Eyestock Rating